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The tumor necrosis factor (TNF) ligand and cognate TNF receptor superfamilies constitute an important regulatory axis that
is pivotal for immune homeostasis and correct execution of immune responses. TNF ligands and receptors are involved in
diverse biological processes ranging from the selective induction of cell death in potentially dangerous and superfluous cells to
providing costimulatory signals that help mount an effective immune response. This diverse and important regulatory role in
immunity has sparked great interest in the development of TNFL/TNFR-targeted cancer immunotherapeutics. In this review, I
will discuss the biology of the most prominent proapoptotic and co-stimulatory TNF ligands and review their current status in
cancer immunotherapy.
1. Introduction
The tumor necrosis factor (TNF) superfamily is comprised
of 27 ligands that all share the hallmark extracellular TNF
homology domain (THD) [1]. This THD triggers formation
of non-covalent homotrimers. TNF ligands are typically
expressed as type II transmembrane proteins,but in most
ligands the extracellular domain can be subject to proteolytic
processing into a soluble ligand. TNF ligands exert their
biological function by binding to and activation of members
of the TNF receptor (TNFR) superfamily. These TNFRs are
typically expressed as trimeric type I transmembrane proteins
and contain one to six cysteine-rich domains (CRDs) in their
extracellular domain [2].
The TNF ligand superfamily has diverse functions in the
immune system, one of which is the induction of apoptotic
cell death in target cells.This function is performed by a fam-
ily subgroup coined the Death Inducing Ligands, comprising
the archetypal member TNF, FasL, and TRAIL. These Death
Inducing Ligands bind to and activate cognate members
of a TNFR subgroup termed the Death Receptors (DRs).
DRs are characterized by the hallmark intracellular Death
Domain (DD) that transmits the apoptotic signal. In general,
ligand/receptor interaction induces formation of a Death
Inducing Signaling Complex (DISC) to the cytoplasmic DD
[3]. This DISC comprises the adaptor protein Fas-associated
death domain (FADD) and an inactive proform of the
cysteine protease procaspase-8. In addition to procaspase-8,
the inhibitory caspase-8 homologue cFLIP can be recruited
to this complex [4]. Within the DISC, caspase-8 is auto-
proteolytically processed via proximity-induced activation
[5], whereupon a catalytic caspase-mediated pathway of
apoptosis ensures execution of apoptotic cell death. All of
these three proapoptotic TNF ligands hold considerable
interest for tumoricidal cancer therapy [6].
A second important function of the TNF superfamily
is the provision of co-stimulatory signals at distinct stages
of an immune response [7]. Such co-stimulatory signaling
is initiated upon TNFL/TNFR interaction and subsequent
recruitment of members of the adaptor protein family of
TNF receptor associated factor (TRAFs) [8]. The TRAF
family consists of 6 members and is characterized by a
highly conserved C-terminal domain that is responsible for
trimer formation and interaction with the TNF receptors.









































Receptor of the tumor
necrosis factor (TNF) family
Ligand of the tumor
necrosis factor (TNF) family
Antibody




















4-1BB+ + target antigen+ cells
Target antigen+ cells alone
(d)
Figure 1: TNFL/TNFR signaling characteristics. (a) TNF-ligands are typically produced as type II transmembrane proteins, but the
extracellular domain of most of these ligands can also be proteolytically cleaved by proteases, such as ADAM-17 (also known as TACE)
[10], into a soluble form. Typically, the soluble ligand retains binding activity but has lost some or all receptor-activating activity. This activity
can be restored by secondary cross-linking. (b) Signaling requirements of 4-1BB-signaling by s4-1BBL. (c) The cross-linking requirement of
sTNF ligands makes their inclusion into an antibody fragment approach attractive. In brief, such a TNFL-fusion protein comprises a scFv
antibody fragment genetically fused to the TNFL.This scFv:TNFL fusion protein is essentially inactive en route. However, upon target binding
of the scFv antibody fragment domain the soluble ligand is converted into a signaling competent membrane-like ligand. (d). Illustration of
target cell-restricted activation by scFv:4-1BBL.
for downstream proinflammatory and prosurvival signal
transduction [9]. Typical signaling pathways activated by
TRAFs are NF𝜅B, PI3K, and PKB. Various co-stimulatory
TNFL/TNFR pairs, including CD40L/CD40, CD70/CD27, 4-
1BBL/4-1BB, and OX40L/OX40, have gained prominence as
possible targets for cancer immunotherapy, in particular with
the aim of induction or (re)activation of antitumor T-cell
immunity.
As briefly mentioned earlier, a prominent feature of
most TNF ligands is their proteolytic processing into sol-
uble trimeric ligands (Figure 1(a)). Many of these soluble
TNF ligands have a significantly reduced signaling activity
compared to their transmembrane counterparts.Whereas the
soluble trimeric ligand typically still binds the receptor, it
requires secondary cross-linking to achieve TNFR activation
reminiscent of its transmembrane TNF ligand counterpart
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as illustrated in Figure 1(b) for 4-1BBL. This feature of the
TNF superfamily has formed the basis for their incorporation
into antibody-based targeted therapies (see Figure 1(c)). In
brief, a TNF ligand is genetically fused to a tumor specific
antibody fragment, yielding a soluble targeted TNF ligand
that is essentially inactive “en route.”Upon antibody fragment
binding to the target cells, this ligand is converted into a
membrane-associated and fully signaling competent form of
the TNF ligand as illustrated in Figure 1(d) for tumor targeted
4-1BBL.
In this review, I will first briefly describe the biology and
then provide an overview of the state-of-the-art of therapeu-
tic exploitation of the proapoptotic ligands TNF, FasL and
TRAIL. Second, I will similarly review several prominent
immune co-stimulatory TNF ligands, in particular CD40L,
CD27L, 4-1BBL, and OX40L. For each of these ligands, I will
further detail the rationale for their inclusion in antibody-
mediated targeting to achieve tumor-selective activity and
reduced toxicity towards normal cells.
2. Tumor Necrosis Factor (TNF)
2.1. TNF Biology. TNF is the archetype superfamily member
and is mainly produced not only by macrophages, but
also by a broad variety of other cells, including lymphoid
cells, mast cells, endothelial cells, fibroblasts, and neuronal
tissue. TNF-alpha interacts with two receptors, namely TNF
receptor 1 (TNFR1) and TNF receptor 2 (TNFR2). TNFR1
is constitutively expressed in most tissues and contains a
cytoplasmic DD and as such is capable of transmitting TNF-
mediated proapoptotic signaling. TNFR2 lacks a cytoplasmic
DD and is expressed predominantly on immune cells and
endothelial cells.
Despite the fact that TNFR1 contains the hallmark DD
required for induction of apoptosis, the main signaling out-
come of TNF/TNFR1 interaction is not apoptotic cell death.
Instead, TNF-induced TNFR1 signaling typically activates
classical nuclear factor kappa B (NF𝜅B) proinflammatory
signaling [11]. In brief, binding of TNF to TNFR1 recruits
the DD-containing adaptor molecules TRADD and RIP1.
TNFR1-bound TRADD subsequently recruits TRAF2 and
cIAP-1 and -2, whereupon NF𝜅B as well as c-Jun N-terminal
kinase (JNK) signaling is induced [12, 13].
Upon receptor internalization this primary complex
dissociates from TNFR1, after which a secondary complex
comprising FADD, procaspase-8 and cFLIP can be formed
[11]. If cellular cIAP and cFLIP levels are limited, this sec-
ondary complex subsequently induces apoptosis via caspase-
8. Notably, binding of membrane TNF to TNFR2 modulates
TNFR1 signaling via proteasomal degradation of TRAF2 and
cIAP. As a consequence, TNFR2 can tip the balance from
inflammatory to apoptotic TNFR1 signaling (reviewed in
[14]).
TNF is a major proinflammatory mediator of the innate
immune system and can exert a large spectrum of bioactiv-
ities. Indeed, TNF modulates a host of (patho)physiological
processes and is, for instance a critical mediator of shock and
involved in both tissue regeneration/expansion and destruc-
tion [14]. As described earlier, the formation of the second
signaling complex also enables TNF to trigger apoptotic cell
death in certain circumstances. For instance, TNF proved to
have potent tumoricidal activity in vitro and inmousemodels
in initial studies [15, 16], a finding that sparked interest in the
development of TNF for cancer therapy.
2.2. Triggering TNF/TNFR Signaling for CancerTherapy. Like
most family members TNF is a transmembrane protein [17],
but its extracellular domain can be proteolytically cleaved
into a soluble form (sTNF) [10]. Of note, TNFR1-mediated
downstream signaling is induced with similar efficacy by
membrane TNF and sTNF (Figure 2(a)). In contrast, TNFR2
is poorly activated by sTNF and requires membrane TNF
for efficient signaling [18]. In preclinical studies, recombinant
sTNF displayed potent tumoricidal activity [16, 19]. Unfor-
tunately, systemic administration of recombinant sTNF only
yielded minimal clinical activity in phase I clinical trials [20,
21] and was, moreover, associated with severe dose-limiting
toxicity already at low doses. These initial findings clearly
negated the use of sTNF as a systemic cancer therapeutic
modality. Nevertheless, locoregional use of soluble TNF in
combination with the chemotherapeutic drug melphalan
yields impressive clinical responses in isolated limb and
isolated liver perfusion [22, 23] and has become part of
clinical practice. In these locoregional applications, sTNF is
infused at over 50 times the maximal tolerated dose (MTD)
as identified during systemic sTNF therapy. This high dose
of TNF triggers endothelial cell apoptosis and subsequent
destruction of the tumor vasculature, whereas normal blood
vasculature is not affected. Consequently, tumor penetration
of melphalan is enhanced.
Of note, the requirement for high concentrations of sTNF
in isolated liver or limb perfusion indicates that in addition
to TNFR1, TNFR2 signaling is required to sensitize tumor
vasculature to apoptotic TNFR1 signaling. In this respect, the
combined use of a low dose of sTNF with a TNFR2-selective
TNF variant may optimize therapeutic effects on tumor
vasculature and minimize toxicity. Of interest in this respect
is a newly reported soluble TNFR2 agonist (TNC-scTNFR2),
in which the trimerization domain of tenascin C (TNC)
was fused to a TNFR2-selective single-chain TNF molecule
comprised of three TNF domains connected by short peptide
linkers (Figure 2(b)) [24]. TNC-scTNFR2 specifically acti-
vated TNFR2 and, importantly, possessed membrane-TNF
like activity towards TNFR2.
2.3. Targeted TNF-Based Cancer Immunotherapy. The major
TNF receptor, TNFR1, is ubiquitously expressed on normal
cells, as a consequence of which soluble TNF has no or
only limited tumor binding selectivity and considerable
toxicity. Further, soluble TNF (sTNF) is practically inca-
pable of triggering TNFR2 signaling and can only efficiently
activate TNFR1, whereas TNFR2 signaling positively affects
the efficacy of TNFR1 apoptotic signaling. All of these
features clearly position TNF for inclusion in tumor targeting
strategies, a strategy that has been pursued by various



























Figure 2: TNF/TNFR signaling and TNFR-targeted therapeutics. (a) TNFR1 and TNFR2 are effectively activated by membrane TNF, but
sTNF can only trigger TNFR1-signaling. (b) TNFR-targeted drugs include a stabilized TNFR2-selective scTNF thatmay help to induce TNFR1
proapoptotic signaling, as well as targeted strategies such as scFv:sTNFL, and scFv:sTNF-TNFR1 prodrug constructs. The latter only become
activated after target antigen-selective binding and subsequent cleavage of the TNFR1 inhibitory domain by tumor-overexpressed proteases.
Such scFv:TNF fusion protein will selectively bind to the
corresponding target antigen via the antibody fragment.This
high affinity interaction will ensure target cell accretion and,
importantly, converts the sTNF domain into membrane-
like TNF. Consequently, target cell-bound scFv:TNF can
efficiently activate TNFR2 and thereby sensitize cancer cells
to induction of TNFR1 apoptotic signaling. Proof of concept
for antibody-mediated delivery of sTNF has been generated
for stromal (FAP), endothelial (integrins), and cellular tar-
gets (e.g., EGFR and Her2) (reviewed in [25]), with very
favorable tumor-to-blood ratios 2-3 days after injection and
potent tumoricidal activity at doses below the Maximum
Tolerated Dose (MTD) of sTNF in preclinical models [26–
28]. Nevertheless, soluble TNF remains highly active towards
TNFR1 expressed on normal cells in the scFv-TNF format.
Further, target antigens used to deliver TNF in these scFv-
TNF fusion proteins are often not tumor specific but tumor
associated or overexpressed, such as the Epidermal Growth
Factor Receptor (EGFR) [29] or Her2 [30]. Consequently,
ubiquitous TNFR1 activation or off-target activation of scFv-
TNF on normal target antigen-positive cells may occur
upon infusion of scFv-TNF fusion proteins with the ensuing
potential for toxicity such as those seen for sTNF [27, 31].
To further decrease the potential for toxicity issues,
strategies that unleash the full tumoricidal potential of sTNF
only at the intended site of action have been developed. Var-
ious recent advances have indeed made significant headway
towards achieving such tumor-selective activation of sTNF.
Firstly, sTNF was genetically fused to a fibroblast-activation-
protein (FAP) specific antibody fragment that additionally
contained the immunoglobulin dimerization domain [32,
33].This dimerization domain ensured that the scFvFAP-TNF
fusion protein formed relatively inactive dimers in solution,
leading to a 10–20-fold reduction in bioactivity compared to
sTNF. However, upon FAP-selective binding the scFvFAP-
TNF fusion protein regained potent TNFR-mediated cyto-
toxicity. Alternatively, antibody fragment-TNF fusion pro-
teins have been C-terminally fused with the ligand-binding
domain of TNFR1. This TNFR1 domain binds and shields
TNF “en route,” yielding an inactive prodrug (Figure 2(b)).
In this prodrug a special linker, designed to be sensitive to
tumor-overexpressed proteases, was incorporated in between
the TNF and TNFR1 domain. Consequently, the inhibitory
TNFR1 fragment present in the prodrug will be cleaved by
tumor overexpressed proteases and shed once at the site of the
tumor. Proof of concept for this prodrug approach has been
generated for the tumor stroma marker FAP with urokinase
plasminogen activator (uPa) and matrix metalloproteinase-2
(MMP2) mediated cleavage of the TNFR1 domain [34, 35].
2.4. Perspectives for theUse of sTNF inCancer Immunotherapy.
The potential for systemic application of sTNF in can-
cer patients critically depends on the tumor-selectivity of
the recombinant sTNF-based drug. The above-described
tumor-targeted antibody fragment-targeted TNF fusion pro-
teins have these properties and should have a significantly
improved toxicity profile while retaining potent tumoricidal
activity. Thus, these targeting concepts generate hope for the
applicability of this cytokine for systemic cancer therapy.
However, it remains to be shown in in vivo follow-up stud-
ies that such more advanced strategies retain effectiveness
and can be sufficiently cleaved and activated at the site
of the tumor. In patients, this will to a great deal depend
on the tumor microenvironmental concentration of active
proteases, a characteristic that will have to be determined
to identify patients likely to benefit from such therapeutics.
Further, TNFR2 selective variants such as discussed earlier
[24] offer the possibility of combining low dose sTNF and
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TNFR2 selective variants possibly in sequential treatment
schedules to generate synergistic apoptotic antitumor activity
with minimal side effects.
Of note, endogenous tumor-produced TNF can have
a remarkable protumorigenic activity [19], for instance
by inducing expression of interleukin 13 receptor alpha
2 (IL13R𝛼2) on tumor resident monocytic cells and the
subsequent production of the immunosuppressive cytokine
TGF-beta [36]. Importantly, antagonistic antiTNF antibody
treatment blocked IL13R𝛼2 expression and restored active
antitumor immune activity in colorectal, fibrosarcoma, and
pancreatic murine models [36, 37]. Thus, for recombinant
sTNF derivatives the intratumoral TNFR cross-linking char-
acteristics as well as intratumor concentration will be of
critical importance to ensure tumoricidal activity in the
absence of any low-dose and sub-optimal signaling mediated
prosurvival signaling. Of note, blocking such prosurvival
signaling may be a target for combinatorial design of TNF-
based drugs with, for example, NF𝜅B inhibitors, such as
parthenolide, or clinical grade proteasome inhibitors such as
bortezomib.
3. Fas-Ligand (FasL)
3.1. FasL Biology. FasL (also known as CD95L) is a type II
transmembrane protein expressed on immune effector cell
such as T-cells.Themain receptor for the ligand of FasL is the
type I transmembrane receptor Fas (CD95) [38, 39], which is
expressed on a variety of normal human cells as a homotrimer
[40–42]. Binding of FasL to Fas triggers oligomerization
of Fas and initiates apoptotic signaling by DISC formation
at the intracellular DD [3]. Of note, nonapoptotic NF𝜅B-
mediated proinflammatory signaling can also be induced
by FasL [43, 44], although this signal is usually overruled
by the apoptotic signaling pathway. However, in cells with
high endogenous levels of apoptosis inhibitors, such as Bcl-
2 or Bcl-xL-expressing cells, NF𝜅B-signaling by Fas can
dominate. FasL can further interact with decoy receptor 3
(DcR3) [45], a soluble receptor that competitively inhibits
FasL/Fas-mediated signaling. Indeed, high circulating levels
of DcR3 have been shown to protect against FasL signaling
in autoimmunity, for instance, by protection of synovial
fibroblasts in rheumatoid arthritis [46].
Next to the granzyme/perforin cytolytic pathway, the
FasL/Fas system represents a major cytolytic effector route of
CD8+ T-cells pivotal for elimination of target cells [47, 48].
Further, Fas-apoptotic signaling is also crucial for the recip-
rocal elimination of activated T cells during the resolution
phase of a T-cell immune response [49, 50]. Of note, likemost
TNF ligands the extracellular domain of transmembrane FasL
is subject to proteolytic cleavage, which generates soluble
homotrimeric FasL (sFasL). Elevated serum levels of sFasL
have been documented in pathological conditions among
others in lymphoma patients [51] and synovial fluid of
rheumatoid arthritis patients [52]. Importantly, processed
sFasL is approximately 1000-fold less effective in inducing
Fas signaling than transmembrane FasL (Figure 3(a)) [53,
54]. Thus, endogenous sFasL likely competitively inhibits the
activity of immune effector cell-expressed full length FasL.
3.2. Triggering FasL/Fas Signaling for Cancer Therapy. The
prominent role of FasL/Fas signaling as cytolytic pathway
in T-cell immunity sparked great interest in its use in
cancer therapy. Indeed, agonistic human antiFas antibody
triggered potent cytotoxicity in human xenografted tumors in
murine models [38]. Unfortunately, upon further evaluation
of Fas-based therapy in syngeneic murine tumor models
and murine Fas-specific antibodies it became apparent that
ubiquitous Fas activation is associated with severe lethal hep-
atotoxicity within 6 h of injection [55]. These early findings
negated the systemic use of Fas agonists for cancer therapy.
Nevertheless, compartmentalized activation of Fas signaling
proved to be effective in murine models without serious
adverse toxicity. For instance, intraperitoneal administration
of sFasL efficiently eliminated murine lymphoma cells in
the absence of toxicity [56]. Together, these data indicate
that compartmentalized use of ubiquitous Fas-agonists or the
design of more target-selective agonists holds considerable
therapeutic potential.
In recent years, efforts have focused on the design of
such more selective tumoricidal Fas agonists. As described
earlier homotrimeric sFasL is inactive/poorly active even at
very high concentrations. However, hexameric recombinant
forms of sFasL, such as Fc-FasL or mega-FasL, were fully
capable of activating Fas-apoptotic signaling in malignant
hematopoietic cells while retaining an acceptable toxicity
profile in mice (Figure 3(a)) [57, 58]. More recently, a
polymeric dodecamer FasL chimera was described in which
FasL was fused to the homotypic aggregation domain of
Leukemia Inhibitory Factor receptor gp1909.Thismultimeric
FasL chimera also proved highly active in vitro, possessed
tumoricidal activity in vivo, and had no liver toxicity at
tumoricidal concentrations [59].Thus, it is possible to design
sFasL variants that possess a clear therapeutic window, at least
in murine model systems.
3.3. Targeted FasL-Based Cancer Immunotherapy. As de-
scribed above, homotrimeric sFasL is inactive but can be
reactivated by virtue of oligomerization. Similarly, immobi-
lization of sFasL on extracellular matrix components restored
membrane FasL-like apoptotic activity [60]. These charac-
teristics establish sFasL as a prime target for inclusion in
antibody-targeted scFv-based therapy (Figure 3(b)). In an
scFv:sFasL-based fusion protein the antibody fragment will
ensure high affinity and selective binding to the predefined
target. Consequently, the inactive sFasL domain is converted
into a membrane-like FasL that can activate Fas-apoptotic
signaling. Proof of concept for this strategy was obtained for
several target antigens, including the tumor stroma marker
FAP [61], the T-cell surface markers CD7 [62], and the B-
cell surface marker CD20 [63]. Specifically, FAP-selective
binding to FAP-positive HT1080 cells induced Fas apoptotic
signaling at a 1000-fold lower ED50 compared to corre-
sponding parental FAP-negative HT1080 cells [61]. Further,
CD7-specific binding of scFvCD7:sFasL triggered apoptotic
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Figure 3: Design of FasL/Fas-based cancer therapeutics. (a) Soluble homotrimeric FasL is essentially incapable of activating Fas-apoptotic
signaling. However, hexamerized recombinant forms of sFasL have Fas-activating capacity analogous to membrane-expressed FasL. (b) The
inactivity of homotrimeric sFasL has been exploited in scFv:FasL fusion proteins, by which the full apoptotic potential of FasL/Fas signaling is
unleashed only upon target antigen-selective binding. To further increase the safety of FasL-based therapeutics, a FasL-based prodrug strategy
analogous to TNF has been designed and evaluated.
elimination of CD7-positive T-cell leukemic cells but lacked
activity on CD7-negative cells [62]. Of note, scFvCD7:FasL
proved inactive towards normal CD7-positive cells, including
resting T-cell and NK-cells. In contrast, activated T-cells
were sensitive to apoptotic elimination by scFvCD7:FasL,
probably due to the intrinsic increase in sensitivity to AICD
occurring in T-cells at later activation stages. In actual fact,
this T-cell restricted activity profile also enabled the selective
elimination of pathogenic synovial fluid T-cells [64].
Interestingly, inclusion of a rituximab-derived antiCD20
antibody fragment in an scFv:sFasL fusion protein revealed a
dual tumoricidal activity [63]. In brief, CD20-selective bind-
ing of scFvRit:sFasL induced CD20-apoptotic signaling, a
finding corresponding with published reports that rituximab
can activate apoptosis by cross-linking of CD20 [65]. Second,
CD20-immobilized scFvRit:sFasL efficiently triggered Fas-
apoptotic signaling. Of note, dual treatment of malignant
B-cells with rituximab and agonistic antiFas antibody also
triggers synergistic apoptotic cell death [66, 67]. However, in
a side-by-side comparison scFvRit:sFasL proved superior to
cotreatment with rituximab and sFasL or antiFas antibody.
3.4. Perspectives for FasL/Fas-Based Cancer Immunotherapy.
To therapeutically exploit Fas-apoptotic signalling it is imper-
ative to prevent ubiquitous activation of this receptor, partic-
ularly in the liver.The use of homotrimeric scFv:sFasL fusion
proteins appear to fulfil this requirement, with as >1000-fold
increase in agonistic activity upon target antigen-selective
binding. However, the safety of this strategy still depends
on the expression pattern of the targeted antigen. Indeed,
most established target antigens in antibody-based therapy
are not tumor specific but tumor associated and tumor-
overexpressed. To further maximize tumor-restricted activa-
tion a pretargeting approach may be developed. For instance,
sFasL can be fused to a fluorescein- (FITC)-specific scFv.
Cancer lesions can be first targeted using an FITC-labelled
antitumor antibody. Once the optimal tumor-to-tissue ratio
has been achieved for this antibody, scFv-FITC:sFasL can be
infused to enable FITC-specific and cancer lesion restricted
accretion of scFv-FITC:sFasL. An analogous approach has
been used for the selective elimination of Fas-scFv-FITC
transduced cells as a conditional death switch [68].
Alternatively, a prodrug scFv:FasL-based strategy anal-
ogous to that reported for scFv:TNF has been pursued to
ensure tumor-restricted FasL-induced signaling [69]. In this
case, the receptor Fas and a TNC trimerization domain
was N-terminally fused via a protease sensitive linker to
the scFv:FasL construct. In this prodrug format, scFv:FasL
fusion remained inactive en route. However, upon target
antigen binding, tumor-overexpressed proteases cleaved the
inhibitory Fas fragment, whereby FasL-apoptotic signalling
was unmasked. Proof of concept in vitro as well as in vivo for
such tumor selective activation was reported for the stromal
marker FAP and the proteases uPA and MMP2 [69].
4. TNF-Related Apoptosis Inducing
Ligand (TRAIL)
4.1. TRAIL Biology. TRAIL is expressed on various immune
effector cells and binds to 4 surface receptors of the TNFR
superfamily, TRAIL-R1 (DR4), TRAIL-R2 (DR5), TRAIL-R3
(DcR1), and TRAIL-R4 (DcR2) (reviewed in [70]). Of these
four, TRAIL-R1 and TRAIL-R2 contain the characteristic
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DD required for induction of apoptosis. TRAIL-R3 is a
phospholipid-anchored receptor, whereas TRAIL-R4 con-
tains a truncated intracellular domain. Consequently, neither
TRAIL-R3 nor TRAIL-R4 are capable of apoptotic signaling
and are thought to have a decoy function. Of note, evidence
for formation of heteromeric TRAIL-receptors comprised
of TRAIL-R2 and TRAIL-R4 highlights an added layer of
complexity to TRAIL/TRAIL-receptor mediated signaling
that is yet to be fully elucidated [71, 72]. TRAIL can further
bind to osteoprotegerin, whereby it may regulate vascular
biology [73] and bone turnover [74].
TRAIL is an effector molecule involved in antiviral and
antitumor immune responses, particularly in tumor immune
surveillance by liver NK-cells, as TRAIL−/− mice develop
increased liver metastases [75]. Expression of TRAIL is
induced by interferons on CD4+ and CD8+ T-cells [76], in
virally infected cells [77], and on multiple myeloma cells
[78]. Further, TRAIL was shown to be required for graft
versus tumor activity upon allogeneic hematopoietic stem cell
transplantation [79].
Apoptotic signaling by TRAIL via TRAIL-R1/-2 is similar
to Fas-induced apoptotic signaling, with formation of the
DISC, processing of caspase-8, and subsequent downstream
caspase-mediated apoptotic signaling. Of note, in the pres-
ence of high levels of endogenous apoptosis inhibitors, such
as cFLIP, TRAIL can also trigger proinflammatory NF𝜅B-
signaling. Such proinflammatory signaling can actually pro-
mote tumorigenicity, as evidenced by a pancreatic cancer
model in which treatment with TRAIL promoted metastasis
formation of xenografted TRAIL-resistant pancreatic cancer
cells [80].
4.2. Triggering TRAIL/TRAIL-Receptor Signaling for Can-
cer Therapy. TRAIL/TRAIL-receptor agonists have shown
prominent tumoricidal activity in a host of preclinical studies
and in a variety of tumor types, whereas no or limited activity
was detected towards normal human cells [81]. Based on this
promising activity profile, a recombinant trimeric form of
TRAIL, named dulanermin, entered phase I/II clinical trials
with no apparent toxicity (reviewed in [82]). Dulanermin is
further being explored in a multicenter clinical trail, with
preliminary results indicating a number of partial responses
and stable disease at higher doses of 8mg/kg [81, 83]. In addi-
tion, combination of dulanermin with antiCD20 antibody
rituximab yielded 2 complete and 1 partial response in non-
Hodgkin lymphoma patients [83, 84], which corresponds to
the reported preclinical synergic activity of rituximab and
TRAILR agonists [85, 86]. Unfortunately, a recent phase
II trial in non small cell lung cancer patients revealed no
added benefit of combined Dulanermin and chemotherapy
treatment [87].
At the same time, a number of TRAIL-R1 and TRAIL-R2
specific agonistic antibodies have entered clinical evaluation,
typically with low to absent toxicity but also without strong
clinical benefit as single agent (reviewed in [88]). Thus,
clinical experience with both TRAIL and agonistic TRAILR
antibodies indicate that real clinical benefit will most likely
require combinatorial therapy. Most ongoing clinical trials
indeed evaluate combination therapy of TRAILR agonists
with, for example, chemotherapy or targeted therapeutics
such as the CD20-antibody rituximab as referred to earlier.
Such combinatorial approaches may also help to overcome
the potential issue of intrinsic resistance to TRAIL, as for
instance observed in ∼50% of tumor cell lines in vitro. In
addition, combinatorial treatment strategies may prevent the
development of acquired resistance to TRAILR agonists.
The potential for acquiring resistance to TRAILR agonists
was demonstrated preclinically upon treatment of cancer
cells with suboptimal concentrations of an antiTRAIL-R2
antibody. Subsequent repeat treatment with therapeutic con-
centrations of the same antibody proved ineffective, whereas
TRAIL and antiTRAIL-R1 still triggered cell death [89]. From
the above it is clear that clinical implementation of TRAILR
agonists will most likely be in the context of combinatorial
strategies that are specifically designed to trigger synergistic
tumoricidal activity.
4.3. Targeted TRAIL-Based Cancer Immunotherapy. The sig-
naling characteristics of the TRAIL/TRAIL-receptor system
are such that sTRAIL appears well suited for use in antibody
fragment-targeted therapy. In particular, whereas sTRAIL
has retained receptor activating potential for TRAIL-R1, it
cannot efficiently activate TRAIL-R2 signaling (Figure 4(a))
[90]. Indeed, TRAIL-R2 activation by TRAIL is reminiscent
of Fas activation by sFasL in that it requires oligomerization
to be effectuated. Further TRAIL receptors are ubiquitously
expressed in the human body, which will limit tumor accre-
tion of sTRAIL. Tumor accretion will further be limited by
the very short half-life of sTRAIL ∼30min in cynamolgus
monkeys, a value which closely corresponded to the half-life
identified in patients in a phase I clinical trial [81, 91].
Fusing sTRAIL to a targeting domain, such as a scFv
antibody fragment, will yield a fusion protein with various
advantageous properties (Figure 4(b)). First, by virtue of
the homotrimerization of sTRAIL, a scFv:TRAIL fusion
protein will have an approximate molecular weight of
180KDa, which is far over the kidney exclusion limit.
Consequently, scFv:TRAIL should have a longer circulation
half-life. Second, the antibody targeting domain will ensure
enhanced tumor-accretion and retention [92–96]. Third,
target-selective binding will convert the sTRAIL domain into
a membrane-like form of TRAIL that can trigger apoptotic
TRAIL-R1 but also TRAIL-R2 apoptotic signaling [97, 98].
The feasibility of this approach has been shown in vitro and
in vivo for both solid tumors and leukemia [92–96]. Of
note, scFv:TRAIL binding triggers TRAIL-receptor apoptotic
signaling in a monocellular, as well as bi- or multicellular
manner. Consequently, neighboring tumor cells that lack the
target antigen can also be efficiently eliminated by the so-
called bystander effect [99].
Rational choice of tumor target antigenwill help optimize
the efficacy of scFv:TRAIL-based therapeutics, as evidenced
by a study using an EGFR-blocking antibody fragment.
Here, the treatment of EGFR-positive tumor cells with
scFv:TRAIL inhibited EGFR-mitogenic signaling and simul-












































Figure 4: TRAIL/TRAIL-receptor signaling and design of TRAILR agonists. (a)Membrane expressed TRAIL triggers apoptotic signaling via
TRAIL-R1 andTRAIL-R2,whereas soluble TRAIL only efficiently activates TRAIL-R1. Recombinant nontargeted sTRAIL thus predominantly
triggers TRAIL-R1 apoptotic signaling. Recombinant TRAIL-R1 or TRAIL-R2 agonistic antibodies can selectively activate TRAIL-R1 or
TRAIL-R2, respectively. (b) Tumor-targeted delivery of sTRAIL, using scFv:sTRAIL, results in conversion of sTRAIL to membrane-like
TRAIL that can induce apoptosis via TRAIL-R1 and TRAIL-R2. The antibody fragment may inhibit or activate target antigen signaling
and thereby contribute to the antitumor activity of scFv:sTRAIL. (c) Targeting of T-cell markers CD7 or CD3 with K12:TRAIL and
antiCD3:TRAIL, respectively, equips T-cells with membrane-like proapoptotic TRAIL that enhances antitumor T-cell activity. The antiCD3
scFv can also trigger stimulatory signaling in resting T-cells and trigger granzyme/perforin-mediated cytotoxicity.
analogous fashion, targeting of the melanoma antigen MCSP
(Melanoma-Associated Chondroitin Proteoglycan Sulphate)
with an scFv:TRAIL fusion protein triggered dual MCSP-
inhibitory signaling and TRAIL apoptotic signaling [100].
MCSP is implicated in metastatic behavior of melanoma
cells [101, 102]. Interestingly, this fusion protein was >100-
fold more effective in colony formation assays that assess
metastatic potential than in direct apoptotic assays. Further-
more, TRAIL inhibition only partly blocked the tumoricidal
effect in colony formation assays, pointing to MCSP-related
therapeutic effects. Thus, scFv-mediated tumoricidal activ-
ity can markedly contribute to the therapeutic activity of
scFv:TRAIL fusion proteins.
In addition to direct tumor-targeting, the scFv targeting
domain can also be used to selectively deliver TRAIL to
the cell surface of immune effector cells, whereby these
cells are equipped with an additional tumoricidal effector
molecule (Figure 4(c)). In a proof of concept study, such
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T-cell targeted delivery of TRAIL, to the T-cell surface
antigen CD3 or CD7, potentiated in vitro antitumor T-cell
activity ∼500-fold and triggered potent tumoricidal activity
in an in vivo engraftment model [103]. Of note, targeted
delivery to CD3 on T-cells also triggered T-cell activation and
potentiated intrinsic cytolytic granzyme/perforin pathway
signaling. From this study it is apparent that rational choice
of T-cell target antigenmay be used to generate dual function
scFv:TRAIL fusion proteins that on the one hand costimulate
T-cells and on the other hand provide the TRAIL-apoptotic
signal for tumor cell killing.
4.4. Perspectives for Use of TRAIL in Cancer Immunotherapy.
From the above it is clear that nontargeted homotrimeric
sTRAIL is safe, but also has sub-optimal apoptotic activity.
Indeed, it is clear that design of combinatorial strategies
of TRAIL with chemotherapy or other targeted drugs is
warranted to achieve clinical efficacy. In preclinical studies,
TRAIL activity is synergized by a plethora of different
established and experimental anticancer drugs. A guideline
for such clinical combinatorial TRAIL-based therapy may be
the choice for a therapeutic that will block potential TRAIL-
mediated prometastatic signaling via NF𝜅B activation, as
reported in preclinical studies for TRAIL-resistant pancreatic
cancer cells [80]. NF𝜅B activation can be effectively blocked
by clinically available proteasome inhibitors such as borte-
zomib [104]. For such combinatorial strategies, a lack of
hepatocyte toxicity is particularly important, as aggregated
forms of sTRAIL strongly reduce hepatocyte viability in
vitro [105] and proteasome inhibition was shown to sensitize
hepatocytes to sTRAIL [106]. Nevertheless, in this latter
study hepatoma cells were significantly more sensitive and
were eliminated at>40-fold lower bortezomib concentrations
than normal hepatocytes, clearly highlighting a therapeutic
window for this combination.
Inclusion of sTRAIL into an scFv:TRAIL fusion protein
can be used to optimize both tumor-selective accretion
and apoptotic activity, which may further be enhanced
by rational incorporation of a tumoricidal scFv. As for
non-targeted TRAIL, combinatorial strategies may help to
optimize activity. In this respect, a recent report identi-
fied promising synergy between bortezomib and an EGFR-
targeted scFv:scTRAIL fusion protein towards hepatoma cells
in the absence of toxic hepatocyte activity [107]. Further,
depending on the relative contribution of the agonistic
TRAIL receptors within a type of tumor, engineered sTRAIL
variants that selectively trigger TRAIL-R1 or TRAIL-R2 may
be used to enhance tumoricidal activity. For instance, the
use of a designed TRAIL mutant with enhanced selectivity
for TRAIL-R1 proved significantly more potent in ∼50%
of EGFR-positive carcinoma cell lines analyzed [92]. Thus,
contributory target antigen signaling as well as the tumor
type intrinsic characteristics of TRAIL-R1/TRAIL-R2 signal-
ing should be taken into account to identify the optimal
scFv:TRAIL protein for respective tumor types.
Additional approaches to optimize TRAIL-based therapy
include the engineering of a single chain TRAIL (scTRAIL)
protein, in which three TRAIL monomers have been geneti-
cally linked [108]. This scTRAIL is a stable homotrimer and
has been incorporated into an scFv:scTRAIL format that
targets Her-2, with prominent Her-2 restricted in vitro and
in vivo activity [108]. Of note, further genetic engineering of
an EGFR-targeted scFv:scTRAIL yielded a dimerized EGFR-
targeted scFv:scTRAIL (Db-scTRAIL) that proved to have 5–
10 fold higher EGFR-restricted activity than the correspond-
ing trimer form [109].
5. Costimulatory TNF Ligands as Inducers of
Effective Antitumor Immunity
Development of the adaptive T-cell immune response is
highly regulated and depends on an elaborate interplay
between T-cell mediated recognition of antigens in the
context of major histocompatibility complexes and the pre-
vailing balance of co-stimulatory and immune-inhibitory
signals. Unfortunately, this intricate multistep system of T-
cell activation provides tumor cells with ample opportunity to
interrupt this process. Indeed, tumor cells have been shown
to hijack components of the T-cell co-stimulatory system
and turn it against the infiltrating T-cell by downregulation
of co-stimulatory and up-regulation of immune inhibitory
signals [110]. In this situation, T-cell receptor interaction with
peptide-loaded major histocompatibility complexes results
in T-cell apoptosis or anergy and a halted tumor immune
response. Further, many tumors have an altered T-cell bal-
ance, with, for example, an increased number of regulatory
T-cells that serve to limit effector T-cell responses [111].
Overcoming these tumor-imposed brakes on immunity can
help to reestablish antitumor immune responses. This is
perhaps best evidenced by the strong clinical benefit of
therapeutic antibodies against immune inhibitory signals,
with the recent FDA approval of the antiCTLA4 antibody
ipilimumab as well as the prominent clinical responses with
antiPD-1 and PD-L1 antibodies reported in clinical trials with
advanced stage cancer patients [112–114].
In addition, insufficient immune co-stimulatory signaling
by tumor necrosis factor (TNF) and TNF-receptor (TNFR)
superfamilymembers further limits the induction of effective
antitumor T-cell immunity. Indeed, co-stimulatory TNFR
signaling is pivotal for effective T-cell immunity and is also
pursued as a therapeutic strategy to induce or restore effective
antitumor immunity [7, 88]. Proof of principle for the validity
of this approach was first obtained over 2 decades ago using
the TNF ligand Lymphotoxin- (LT) alpha. LT-alpha is a
soluble ligand that binds to TNFR1 and TNFR2, but like
sTNF only effectively stimulates TNFR1 [115, 116]. Targeted
delivery of LT-alpha induced de novo formation of lymphoid-
like tissue in the tumor microenvironment, leading to T-cell
mediated antitumor rejection. Unfortunately, LT-alpha also
signals via TNFR1, with the potential for systemic effects as
found for sTNF, which precludes its systemic administration
to humans.
In the past decades several co-stimulatory TNFL/TNFR
pairs have gained prominence as possible therapeutic mod-
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Figure 5: Co-stimulatory TNF ligands provide crucial signals for generation of antitumor T-cell responses. Within the antitumor T-cell
immune response, CD40L-mediated CD40 costimulation of DCs by CD4+ T-helper cells is critical for the generation of CD8+ T-cell
responses. 4-1BBL expressed onDCs stimulates the generation of T-cell response, while at the same time inhibiting the formation of inducible
regulatory T-cells in the tumor micro-environment. CD70 serves to efficiently prime CD4+ and CD8+ T cell responses, to enhance T-cell
survival, and to optimize effector function. OX40 is transiently upregulated upon T-cell activation and enhances clonal expansion, survival,
proinflammatory cytokine production, and generation of memory CD4 T-cells and enhances CD8+ T-cell survival and expansion.
CD70/CD27, 4-1BBL/4-1BB, and OX40L/OX40 (Figure 5).
These various TNF ligands provide a co-stimulatory signal at
distinct stages of the immune response to ensure the ultimate
generation of functional immunity [117]. A host of preclinical
data indicated that reactivation of antitumor T-cell immune
responses using agonistic antibodies that target respective co-
stimulatory receptors triggers potent antitumor immunity in
mouse studies.
However, an important concern with the use of agonistic
antibodies that target the co-stimulatory TNFL/TNFR axis
is the potential for deleterious side-effects due to ubiquitous
TNFR signaling. Indeed, clinical trials with 4-1BB agonistic
antibodies have been terminated after severe hepatic adverse
events [118], while clinical trials with CD40 agonists were also
associated with significant toxicity [119, 120]. Thus, it is of
great interest to design strategies that restrict co-stimulation
and subsequent immune activation to the cancer lesion. In
the section next I will discuss the biology of CD40L/CD40,
CD70/CD27, 4-1BBL/4-1BB and OX40L/OX40 and highlight
their current status for cancer immunotherapy. Further, I
will discuss the rationale for incorporating these ligands into
antibody-fragment targeted delivery of soluble TNFLs to the
tumor.
6. CD40L Biology
CD40L is a type II transmembrane protein transiently
expressed on activated CD4+, CD8+, and 𝛾𝛿 T-cells [121].
Further, CD40L expression has been identified on mon-
ocytes, activated B-cells, epithelial cells, endothelial cells,
platelets, smooth muscle cells, and DCs. Expression of its
cognate receptor CD40 is found on B-cells, monocytes,
macrophages, platelets, DCs, eosinophils, and activated
CD8+ T-cells [122–124].
One of the main functions of the CD40L/CD40 sys-
tem is to activate and “license” DCs to prime effective
cytotoxic CD8+ T-cell responses [125, 126]. In brief, co-
stimulatory CD40L on antigen-specific CD4+ T helper cells
interacts with CD40 on DCs, which triggers a multipronged
response with upregulation of CD40, increased DC survival,
upregulation of T-cell co-stimulatory molecules CD80 and
CD86, an increase in the expression and stability of MHC
class II-peptide complexes, and induction of inflammatory
cytokines, such as immunostimulatory cytokine IL-12 [127,
128]. Together, these effects serve to “license” DCs and to
stimulate the generation of effective CD8+ T-cell response.
In the absence of CD40 signaling, activation of CTLs by
so-called “unlicensed” DCs induces T-cell anergy or T-cell
deletion and generates regulatory T cells [129]. Importantly,
induction of CD40 signaling on DCs using, for example,
agonistic antibodies can substitute for CD4+ T-cell help
and directly stimulate a specific CD8+ CTL response [125,
130], highlighting a clear rationale for CD40-based cancer
immunotherapy.
6.1. Triggering CD40L/CD40 Signaling for Cancer Therapy.
The major aim of therapeutic targeting of CD40 is the
induction of efficient DC-mediated priming of T-cell immu-
nity and ensuing induction of effective antitumor T-cell
immune responses. This aim has been pursued using various
approaches, first and foremost with agonistic antibodies and
recombinant forms of soluble CD40L (Figure 6). A human
CD40L variant fused to an isoleucine zipper trimerization
domain yielded prominent induction of T-cell immunity
and tumoricidal activity in preclinical models (Figure 6)
[131]. Similarly, agonistic CD40 antibodies yielded potent
antitumor T-cell immunity in mice [132]. Both recombinant
CD40L and an agonistic antiCD40 antibody (CP-870.893)
advanced into early stage clinical trials in cancer patients [119,
120]. In these clinical trials, systemic treatmentwas associated
with significant and dose-limiting toxicity, with the MTD
of sCD40L already reached at the low dose of 0.1mg/kg.
Nevertheless, CP-870.893 induced partial responses in 15%–
20% of advanced stage melanoma and pancreatic adenocar-
cinoma patients [133–135], highlighting the promise of CD40
targeting.
Of note, CD40 is also expressed on various malignancies
[136]. On many of these malignant cells, the cross-linking of
CD40 triggers apoptotic cell death or inhibits proliferation,



























Figure 6: CD40L/CD40-based agonists for cancer therapy. Soluble CD40L is only capable of sub-optimal CD40 signaling. However,
enforced trimerization of CD40L or agonistic antiCD40 antibodies can trigger effective CD40-signaling, but with severe side-effects due
to ubiquitous CD40-activation. Of note, CD40 agonist antibodies require FcR-mediated cross-linking for effective CD40-signaling. In an
antibody fragment-targeted scFv:CD40L fusion protein, the CD40L domain is relatively inactive en route, but gains membrane-like activity
upon target antigen-mediated binding. Further, CD40L can be virally transduced into tumor cells, using AdCD40L, to optimize CD40-
mediated co-stimulation.
ascites-derived ovarian carcinoma cells [137]. This contrasts
with the typical CD40-mediated prosurvival and proliferative
signaling on normal human cells. CD40-mediated inhibition
of proliferation has also been observed in high grade B-cell
lymphoma derived cell lines in vitro as well as in vivo, suggest-
ing that cytotoxic antiCD40 therapy is a potential strategy for
B-cell lymphoma. In line with this, the antiCD40 antibodies
dacetuzumab (SGN-40) and lucatumumab (HCD122) are
being evaluated in various phase I/II trials [88]. Thus CD40
targeted therapy may have a dual beneficial effect comprising
direct tumor cell signaling, leading to growth arrest or
even apoptosis, and DC-dependent stimulatory activity on
antitumor T-cell immunity.
6.2. Targeted CD40L/CD40-Based Cancer Immunotherapy.
Despite the obvious promise of CD40-targeted immunother-
apeutics, the applicability is hampered by systemic and dose-
limiting toxicity towards normal cells in patients. Indeed,
agonist antiCD40 treatment of mice was already associated
with considerable inflammatory side effects. Thus, to further
advance CD40 as a therapeutic target it is imperative to
enhance the selectivity of CD40 stimulation. Accumulating
evidence indicates that CD40 signaling is only initiated when
CD40 is clusteredwithin themembrane of target cells. In fact,
CD40 signaling induced by antiCD40 antibodies critically
depends on Fc-receptor positive cells that provide requisite
Fc-mediated clustering of CD40 [138]. Thus, in the absence
of sufficient cross-linking the antiCD40 signal is ineffective
in generating immunostimulatory signals (Figure 6). For sol-
uble CD40L (sCD40L), evaluation of cross-linking require-
ments revealed that a trimeric Flag-tagged form of sCD40L
could already trigger CD40-signaling [139]. Nevertheless, the
efficacy of signaling was increased ∼10-fold upon antiFlag
antibody-mediated cross-linking. In line with this finding, a
hexameric form of sCD40L proved fully capable of activating
DCs and inducing T-cell responses [139, 140]. Analogously,
an oligomeric surfactant proteinD (SP-D)CD40L fusion pro-
tein efficiently triggered CD40-dependent B-cell proliferative
effects, whereas trimeric sCD40L proved minimally active
[141]. This oligomeric form of CD40L was recently found
to also effectively stimulate antiHIV immune responses in
combination with an HIV-1 Gag vaccine [142].
Based on these cross-linking requirements for CD40/
C40L signaling, CD40L has also been included in a FAP-
targeted scFv:CD40L antibody fragment-based fusion pro-
tein (Figure 6) [139]. In brief, antibody fragment-specific
delivery will ensure FAP-specific accretion and the sub-
sequent display of multimeric/oligomerized CD40L for
effective induction of CD40 signaling on DCs. Indeed,
FAP-specific binding of scFv:CD40L triggered an ∼25-fold
decrease in ED50 for IL-8 production in target cells.
In addition to systemic treatment with CD40 agonists
various alternate CD40-based strategies have been investi-
gated in order to optimize DC activity. Of those, adenoviral-
based immunostimulatory gene therapy using AdCD40L is
of particular interest (Figure 6) [143]. In brief, adenoviral
infectionwill trigger Toll-like receptor (TLR) signaling, while
the transgene CD40L potentiates DC activity. AdCD40L can
be used for ex vivo gene modification of tumor cell vaccines
or for direct intratumoral injection and has proven efficacious
in murine models. Further, AdCD40L proved safe in humans
and induced clinical responses in early clinical trials [144–
146].
In an alternative approach to optimize DC vaccination a
bi-specific co-stimulatory diabody comprising antiCD40 and
antiCD28 was constructed [147]. This diabody was designed
to simultaneously target and activate stimulatory CD40-
signaling on DCs and CD28-signaling on na¨ıve T cells.
Using this diabody, the strength and duration of T cell/AML-
DC interactions and the responsiveness of T-cells to AML
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antigenswas increased. In addition, CD40L can be genetically
fused to a vaccine antigen in order to enhance the immuno-
genicity of the vaccine. For instance, transfection of DCs with
a plasmid containing a genetic fusion between theHepatitis B
virus (HBV) S gene and CD40L upregulated DC maturation
markers, triggered IL-12 secretion, and stimulated allogeneic
T-cell proliferation [148]. Finally, the previously described
multimeric SP-D-CD40L fusion protein was recently using in
an adoptive T-cell expansion protocol, in which it efficiently
expanded and generated APC-like B-cells ex vivo that could
trigger CD8+ T-cell expansion [149, 150].
6.3. Perspectives for sCD40L/CD40 in Cancer Immunotherapy.
Agonistic triggering of CD40 holds considerable promise
as an anticancer therapeutic strategy and likely will trigger
both direct antiproliferative and/or proapoptotic signaling in
CD40-positive tumor cells as well as induction of antitumor
T-cell immune responses. A main current focus of CD40
agonist research is on the design and evaluation of combined
therapy of CD40 agonists with, for example, chemotherapy or
other immunomodulators such as antiCTLA-4 antibody.
For the clinical use of agonistic CD40 therapeutics it
is imperative to achieve higher tumor selectivity to ensure
an acceptable toxicity profile. Of interest in this respect is
a recent report in which antiCD40 antibody was given at
low-dose intra or peritumorally in a slow-release formulation
[151]. This strategy resulted in local activation of tumor-
specific CD8+ T cells without causing systemic toxicity
by nonspecific and ubiquitous CTL activation. Enhanced
tumor selectively can also be achieved by antibody-targeting
strategies such as the scFv:CD40L fusion protein referred
to earlier [139]. Further, the requirement of CD40 agonistic
antibodies for FcR-mediated cellular cross-linking opens the
possibility of generating bi-specific antibodies that on the
one hand target a tumor associated antigen and on the other
hand comprise an antiCD40 antibody fragment. In principal,
CD40 signaling will only be initiated upon tumor specific
binding of the bi-specific antibody fragment thus ensuring a
restricted CD40 co-stimulatory signaling.
Potential advances on DC-targeted vaccination strategies
include CD40L delivery to tumor cells using an oncolytic
adenoviral vector [152, 153]. Infection of tumor cells with
oncolytic vectors will trigger tumor cell death, thereby boost-
ing tumor antigen release in the tumor micromilieu, while
the CD40L transgene is designed to ensure optimal DC/T-
cell interaction [152, 153].
Of note, although it is clear that CD40/CD40L signaling
can potently augment antitumor immune responses, recent
studies also highlight a potential immunosuppressive effect of
soluble trimeric CD40L [154]. The serum of cancer patients
contains significantly elevated levels of sCD40L compared
with healthy donors [155]. Further, recombinant trimeric
sCD40L triggered enrichment ofmyeloid-derived suppressor
cells (MDSCs), expansion of Treg, and inhibited effector T-cell
proliferation [155].These findings highlight the importance of
evaluating possible unanticipated immune inhibitory effects
of sub-optimal CD40 activation by CD40L-based agonists
and of the influence of serum sCD40L on therapy outcome.
This may ultimately lead to inclusion of serum CD40L as a
patient stratification marker.
7. CD70/CD27 Biology
The ligand CD70 (also known as CD27L) is a predicted type
II homotrimeric transmembrane family member of the TNF
family [156, 157]. Unlike most other TNF ligands, CD70 has
not been found to contain putative cleavage motifs in the
extracellular domain and is thus expected to exist only as a
transmembrane protein. The expression of CD70 on normal
cells is restricted to activated T- and B-lymphocytes and
mature DCs [158].
The cognate receptor for CD70 is CD27, a type I trans-
membrane receptor expressed on naive T cells, mature T-
cells, memory B-cells, and NK-cells [158]. Cross-linking of
CD27 triggers recruitment of the adaptor proteins TRAF2
andTRAF5 to its cytoplasmic domain, leading to activation of
canonical and noncanonical NF𝜅B signaling and c-Jun kinase
signaling. Of note, CD27 is expressed as a homodimer on
the cell surface [159], suggesting that functional CD70/CD27
interaction occurs at least in a hexameric form. In contrast to
CD70, CD27 can be proteolytically processed into a soluble
form that may serve as a competitive inhibitor [160].
The key biological function of CD70 is to efficiently prime
CD4+ and CD8+ T cell responses, to enhance T-cell survival,
and to optimize effector function [158, 161–163]. As such,
CD70 appears to be a crucial co-stimulatory molecule that
is required for the induction of T cell immune responses
[158]. In particular, CD27 is present on resting T-cells and
is further upregulated upon T-cell activation [156, 164, 165].
This upregulation of CD27 on effector T-cells is transient and
strongly correlates with effector function [166]. In line with
a critical role for CD27 in T-cell activation, both primary
and secondary T cell responses are impaired in CD27−/−
mice [167]. CD70/CD27 signaling promotes the development
of CD4+ T-cells producing either TH1 or TH2 type effector
cytokines [168], suggesting that CD70/CD27 signaling can
trigger a broad spectrum of immune responses.
7.1. CD70/CD27 as Targets for Cancer Immunotherapy. Many
types of hematological and solid tumors have been docu-
mented to express CD70 on the cell surface [169], whereas
CD70 is only transiently expressed on antigen-activated lym-
phocytes on normal cells. This expression pattern establishes
CD70 as a potential target for antibody-based cancer therapy
(Figure 7). Indeed, antiCD70 antibodies have shown con-
siderable preclinical efficacy towards hematological malig-
nancies. For instance, the humanized IgG1 antibody SGN-
70 eliminated CD70-positive tumor cells leading to tumor
regression in disseminated lymphoma andmultiple myeloma
xenograft models [170], in this case via typical antibody
effector functions, such as ADCC and CDC.
In addition to its tumor-restricted expression pattern
research has focused on the potential reactivation of anti-
tumor T-cell immunity by agonistic CD27-targeted therapy
(Figure 7). The rationale for this approach is emphasized by
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Figure 7: CD70/CD27-based agonists for cancer therapy. CD70 is highly expressed onmalignant cells and thus a bona-fide target for antiCD70
antibody based therapy. Similarly, scFv-targeted TRAIL/FasL-based fusion proteins could be used to selectively deliver and locally activate
proapoptotic signaling. Triggering CD27 T-cell co-stimulatory signaling may be particularly applicable in, for example, ex vivo expansion of
adoptive T-cells. Incorporation of an antiCD27 scFv in a bispecific antibody format with a tumor-specific targeting antibody fragment may
open up ways to ensure selective modulation and/or inhibition of CD27 signaling in the tumor micro-environment.
mice upon tumor challenge [161]. Correspondingly, agonistic
triggering of CD27-signaling ensured generation of a tumor-
specific T-cell response and protected against lymphoma,
melanoma, and fibrosarcoma tumor growth upon i.v. or s.c.
tumor challenge [161, 171–173].
However, a recent study identified that in established
tumor models, CD27 signaling actually promoted tumor
growth, with a reduction in Treg apoptosis and production
of the Treg survival cytokine IL-2 by CD4+ effector T cells
(TEff ) [173]. In line with this, the frequency of Tregs and
the growth of solid tumors was reduced in CD27-deficient
mice or in wild-type mice treated with an antagonistic
CD27 monoclonal antibody. Indeed, such a CD70-mediated
expansion of Tregs corroborates with the proposed role of
CD70 in tumor immune escape in renal cell carcinoma [174].
Thus, in the tumor micro-environment CD70 may promote
tumor growth and immune evasion.
7.2. Perspectives for CD70/CD27 in Cancer Immunotherapy.
CD70 is highly expressed on various types of cancers and
as such is a bona fide target for antiCD70 antibody medi-
ated therapy. Thus, antiCD70 antibodies are well-positioned
for, for example, B-cell lymphoma, where preclinical data
revealed potent tumoricidal activity [170]. Due to its selective
expression profile CD70 may also be a target for design of
TRAIL, FasL, or TNF- (prodrug-) based antibody fragment-
targeted fusion proteins as well as antibody-drug conju-
gates/immunotoxins (Figure 7). Further advances in CD70
cytotoxic therapy can be anticipated for combinationwith, for
example, cytotoxic debulking therapy.
However, caution is required in terms of exploit-
ing the immunoregulatory role of CD70/CD27 for can-
cer immunotherapy. Although the CD70/CD27 axis has
prominent immunostimulatory activity in de novo induced
immune responses, its role in the established tumor micro-
environment appears paradoxically opposite, with the expan-
sion and prolonged survival of Tregs [173]. Thus, it is impera-
tive to consider the aim of CD70/CD27-based immunother-
apy and adapt the strategy accordingly. For instance, upon
inclusion in, for example, tumor vaccination strategies, where
a de novo antitumor T-cell response is induced, adjuvant
use of a CD27 agonist may help optimize T-cell responses.
Similarly, ex vivo expansion of T-cells for subsequent adoptive
T-cell transfer experiments may benefit from CD27 ago-
nists (Figure 7). In contrast, in a combination approach of
CD70/CD27 targeting with conventional cytotoxic therapy,
it may be more appropriate to incorporate an antagonistic
CD27 antibody.Hereby, the Treg-induced brake on existing T-
cell immunity is released. Of note, incorporation of CD27 in
a bispecific antibody format with a tumor-specific targeting
antibody fragment may open up ways to ensure selective
modulation and/or inhibition of CD27 signaling in the tumor
micro-environment (Figure 7). Further preclinical studies
are needed to evaluate whether this dualistic and context-






























Figure 8: 4-1BBL/4-1BB. Soluble 4-1BBL or hexameric 4-1BBL is essentially inactive. However, enforced oligomerization using SA-4-1BBL
enables 4-1BB activation with a favorable toxicity profile. In contrast, agonistic 4-1BB antibodies potently activate 4-1BB signaling but with
dose-limiting toxicity.The selective use of 4-1BB co-stimulatory signaling can potentiate CART-cell activity and trigger effective lysis. Further,
selective delivery of 4-1BBL using scFv:4-1BBL ensures target antigen-restricted conversion of inactive s4-1BBL into membrane-like and
signaling competent 4-1BBL.
8. 4-1BBL/4-1BB Biology
4-1BB (also known as CD137) is an inducible co-stimulatory
receptor expressed on activated T-cells as well as activated
NK-cells but is constitutively expressed on regulatory T-
cells [175]. In fact, 4-1BB expression has been used in a
recent study as a marker to identify and isolate natural Treg
from peripheral blood mononuclear cells [176]. The ligand
for 4-1BB, 4-1BBL, is predominantly expressed on activated
antigen presenting cells such as Dendritic cells, B-cells and
macrophages [175]. Interestingly, DCs not only express 4-
1BBL, but can also express 4-1BBupon activation although the
consequence of this co-expression is unclear. Co-stimulatory
signaling by 4-1BBL/4-1BB proceeds via recruitment of
TRAFs to the cytoplasmic domain of 4-1BB [177], which
triggers downstream activation of NF𝜅B, PKB, and PI3K
pathways and upregulates antiapoptotic proteins such as Bcl-
xL [178, 179].
The inducible expression of 4-1BBL on APCs and 4-1BB
on T-cells implied an important role for this ligand/receptor
pair in T-cell co-stimulation. Indeed, 4-1BB triggering on
T-cells using either an agonistic anti4-1BB antibody or
recombinant 4-1BBL enhanced the proliferation as well as the
cytokine secretion in vitro in both CD4+ and CD8+ T-cells
[180, 181]. However, 4-1BB co-stimulatory activity appears
to preferentially expand CD8+ T cells over CD4+ T cells
[182], with enhanced CD8 T cell survival and inhibition
of activation-induced cell death [179, 183–185]. In line with
this, 4-1BBL−/− mice are characterized by a decreased CD8-
specific T-cell response [186–188].
8.1. Triggering 4-1BB/4-1BBL Signaling for Cancer Therapy.
The 4-1BBL/4-1BB co-stimulatory axis has a multifold effect
on cancer immunology and has therefore been a prime target
for therapeutic manipulation, also based on the finding that
various tumor infiltrating T-cells express 4-1BB [189]. Ago-
nistic 4-1BB antibodies trigger effective antitumor immune
responses in a variety of mouse models (Figure 8) [190,
191]. However, ubiquitous activation of co-stimulatory 4-
1BB signaling was associated with severe toxicity in murine
models [192, 193]. Indeed, although in an initial phase I
trial the anti4-1BB antibody (BMS-663513) had tolerable
side effects, a follow-up Phase II trial revealed severe liver
toxicity in ∼10% of the patients, with 2 fatalities at doses
>1mg/kg. As a consequence, trials with systemic agonis-
tic anti4-1BB antibody were terminated, although a dose-
escalation study has resumed (NCT01471210). These data
point to the fact that more tumor-selective 4-1BB activation
is needed. In this respect, a recombinant fusion protein
comprising streptavidin (SA) fused to murine soluble 4-
1BBL, yielding oligomeric 4-1BBL proved safe and effective
in murine models (Figure 8) [194]. SA-4-1BBL was also
reported to inhibit the formation of induced Treg (iTreg), that
normally limit T-cell immune response in the tumor micro-
environment, and to make CD4+ and CD8+ effector T-cells
(TEff ) cells refractory to Treg activity [195]. Consequently, the
intratumoral TEff /Treg cell ratio increased, which correlated
with therapeutic efficacy in various preclinical tumormodels.
Such an elevated TEff /Treg ratio is predictive of survival
in various types of cancer, for example, in ovarian cancer
patients [196].
Of note, SA-4-1BBL has also been positioned for vaccina-
tion strategies, in which biotinylated primary isolated tumor
cells can be rapidly loaded with 4-1BBL [197]. Here, 4-1BBL
provided co-stimulation and optimized vaccine-mediated T-
cell immune responses. The efficacy of DC-based vaccines
can also be enhanced by gene-pulsing DCs ex vivo with 4-
1BBL [198]. Such 4-1BBL expressing DCs trigger enhanced
T-cell activation and increased IFN-𝛾 production, suggesting
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that 4-1BBL is a suitable adjuvant to optimize DC-based
cancer immunotherapy.
4-1BB signaling has also been exploited to enhance the
efficacy of so-called Chimeric Antigen Receptor (CAR) T-
cells. In brief, a CAR is a T-cell transduced with a modified
T-cell receptor that comprises the intracellular signaling
domain of the CD3 zeta chain fused to an extracellular
antitumor scFv antibody fragment [199]. This antitumor
antibody fragment retargets the CAR to tumor cells, where-
upon the CD3 zeta chain triggers T-cell activation. More
recent CAR T-cells have been engineered to additionally
contain the intracellular signaling domain of 4-1BB, which
provides a second co-stimulatory signal (Figure 8). A recent
clinical trial with a CD19 specific CAR yielded exciting
effects, with the infusion of moderate dose autologous CAR
T-cells triggering therapeutic activity in all three advanced
CLL patients and a complete remission in 2 of the patients
[200, 201]. An important cautionary note for including co-
stimulatory domains in CAR T-cells was learned when an
Her2-specific CAR containing dual intracellular 4-1BB and
CD28 co-stimulatory domains proved fatal upon infusion in
the patient [202].
The 4-1BBL/4-1BB co-stimulatory axis has been mainly
investigated in terms of T-cell immune responses. However,
the antitumor efficacy of 4-1BB stimulation in mice appears
to partly rely on NK-cell activity [203]. In line with this, ex
vivo stimulation of PBMCs of healthy donors or patients with
renal cell or ovarian carcinoma with a combination of soluble
4-1BBL and IL-12 induced a long-term proliferation of func-
tional CD56bright NK cells [204]. These data further confirm
the role of 4-1BBL/4-1BB in NK-cell biology and highlight
that inclusion of s4-1BBLmay optimize ex vivo expansion and
activation of NK cells for cancer immunotherapy.
8.2. Targeted 4-1BBL-Based Cancer Immunotherapy. As with
the other ligand/receptor pairs discussed in this review, both
4-1BB and 4-1BBL are naturally occurring homotrimers.
However, activation of 4-1BB with 4-1BBL requires oligomer-
ization, with trimeric soluble 4-1BBL being approximately
100-fold less active than oligomerized 4-1BBL [139]. This dif-
ferential activity profile positions 4-1BBL as a potential effec-
tor domain for antibody fragment-targeted immunotherapy.
Indeed, proof of concept for restricted activation of 4-1BB-
mediated co-stimulationwas obtained for targeted delivery of
4-1BBL to the tumor stroma marker FAP using an scFvFAP-
1BBL fusion protein (Figure 8) [205]. In cocultures of FAP-
expressing HT1080 cells and T-cells, the fusion protein
provided co-stimulatory signals. In contrast, in cocultures
with parental FAP-negative HT1080 and T-cells, scFvFAP:4-
1BBL was inactive. Together, these reports indicate that
target cell-dependent co-stimulation with scFv:4-1BBL may
enhance tumor-restricted T-cell activation and improve T
cell-mediated antitumor immunity.
8.3. Perspectives for 4-1BBL/4-1BB in Cancer Immunotherapy.
Although systemic 4-1BB treatment is associated with severe
toxicity, the 4-1BB/4-1BBl axis remains of great interest and
various approachesmay be used to increase tumor specificity.
For instance, a recent report explored spatiotemporal infu-
sion of adoptive T-cell transfer and 4-1BB. In brief, adoptively
transferred T-cells were first infused and were found to
upregulate 4-1BB expression only at the site of tumor, thus
yielding a therapeutic window for 4-1BB agonist treatment 3
days after lymphocyte infusion [206]. In addition, combined
use of 4-1BBL with T-cell retargeting strategies may yield
an MHC-unrestricted potent antitumor immune response.
The potential for such a strategy has been recently shown,
with a combination of T-cell retargeting bispecific antibody
and scFv:4-1BBL fusion protein, yielding a strongly enhanced
cytotoxic T-cell response [207]. In brief, the bispecific anti-
body providedMHC-unrestricted tumor recognition and the
primary CD3-mediated activation signal, whereas endoglin-
targeted 4-1BBL provided the crucial second T-cell activation
signal. Further, combination of a 4-1BBL-expressing tumor
cell vaccine with antibody-mediated blockade of CTLA-4
proved superior to tumor cell vaccine alone [208]. Here, the
combination triggered regression of established tumors and
yielded a significant increase in survival in mice. Similarly,
tumor targeted delivery using scFv:4-1BBL may be used
to maximize CAR T-cell activity. Here, sequential dosing
may help to optimize tumor-restricted CAR activation and
improve on the safety profile of the CAR technology.
9. OX40L/OX40 Biology
Another prominent candidate for the (re)activation of active
T-cell immunity is the ligand/receptor pair OX40L/OX40.
OX40 (CD134) was named after the antibody clone OX40
that was originally used to identify this receptor on activated
CD4+ T-cell blasts [209]. OX40 was later also identified on
CD8+ T-cells, NK cells, NKT cells, and neutrophils [210].
OX40L is primarily expressed on antigen presenting cells,
such as DCs, B-cells, and macrophages, but is also expressed
on freshly isolated NK-cells where it is further upregulated
upon activation [211]. In addition, OX40L is expressed on the
basal side of endothelial cells at sites of inflammation, where
it may provide a crucial co-stimulatory signal to extravasated
T-cells.
OX40 intracellular signaling proceeds in particular via
TRAF2 and TRAF5 and activates downstream canonical
and noncanonical NF𝜅B signaling, PI3K and PKB pathways.
OX40 signaling upregulates the antiapoptotic proteins Bcl2,
Bcl-xL, and survivin ∼4–6 days following TCR-ligation and
thereby provides a crucial survival signal to CD4+ and CD8+
T-cells [212–214]. Indeed, in OX40−/− T-cells the expression
of these antiapoptotic proteins is downregulated [212]. OX40
provides a co-stimulatory signal to sub-optimally and low-
dose TCR-stimulated T-cells and enhances clonal expansion,
survival, proinflammatory cytokine production, and gener-
ation of memory CD4 T-cells [215–218]. Further, OX40 also
directly enhances CD8+ T-cell survival and expansion as well
as indirectly stimulates CD8+ T-cell expansion via induction
of CD4+ T-cell helper responses [219, 220].
Importantly, expression of OX40 on T-cells is transient
and first becomes detectable ∼12–24 h after T-cell receptor
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Figure 9: OX40L/OX40. Soluble OX40L can only suboptimally activate OX40 co-stimulatory signaling. Hexameric recombinant OX40L is
fully capable of activating OX40-signaling like OX40 agonistic antibodies, with no dose-limiting toxicity of such an OX40 antibody in an
early clinical trial. To increase tumor selectivity, sOX40L can be targeted to tumor cells using scFv:OX40L. The sOX40L domain will convert
into membrane-like and fully signaling competent OX40L only upon selective binding to the targeted antigen.
(TCR) ligation on both activated CD4+ and CD8+ T-cells
[221]. After 48–96 h, the expression of OX40 on these acti-
vated T-cells is downregulated [221]. This temporal expres-
sion profile of OX40 corroborates with the required timing of
therapeutic OX40 antibodies, which need to be given 1-2 days
after antigenic stimulation [215]. During antigen recall, OX40
is rapidly expressed onmemory T-cells within 1–4 h. Of note,
OX40 is also constitutively expressed on T-regulatory (Treg)
cells in mice [166], but human Treg express no or minimal
OX40 although it can be up-regulated during inflammation.
9.1. Triggering OX40L/OX40-Signaling for Cancer Therapy.
Since the initial report describing OX40 expression on
tumor-infiltrating T-cells in melanoma and head and neck
cancer patients [222], the therapeutic targeting of the
OX40L/OX40 axis for cancer therapy has been pursued using
agonistic OX40 antibodies or recombinant forms of soluble
OX40L (e.g., OX40L:Fc) (Figure 9) [131, 223]. In various
preclinical models of immunogenic tumors, such as CT26
colon cancer andMC303 sarcoma, OX40 antibody treatment
was shown to eradicate tumor outgrowth [223, 224]. Based
on these results a clinical trial was initiated with a murine
antiOX40 monoclonal antibody (9B12). In this phase I trial
of 30 patients a single bolus injection of 9B12 did not reach
the maximum tolerated dose (MTD) and was associated with
a relatively mild toxicity profile [225]. Importantly, patients
receiving antiOX40 treatment had an increase in tumor-
specific immune responses after therapy and had increased
CD4+ and CD8+ T-cell proliferation. However, no objective
clinical responses were detected, although some patients
did experience tumor shrinkage. Of note, the detection of
human antimouse antibody (HAMA) responses after single
treatment highlights the need for development of a human-
ized antiOX40 antibody, which is currently being pursued.
An alternative OX40 agonist is a recombinant hexameric
humanOX40L:Fc, comprising a trimerizing isoleucine zipper
(ILZ) domain, which had superior biological activity as
soluble therapeutic in vitro compared to antiOX40 antibody
treatment [131], positioning OX40L-based therapeutics as
viable alternative to agonistic OX40 antibodies.
However, in poorly immunogenic tumors single agent
antiOX40 treatment does not provide adequate antitumor
immunity, as a result of which combination of OX40 with
other strategies has been pursued. In this respect, combi-
nation of OX40 with the Treg depleting chemotherapeutic
drug cyclophosphamide triggered a combined depletion of
intratumoral regulatory T-cells and an influx of CD8+ CTL,
which together yielded strong tumoricidal activity [226]. In
line with this report, Treg depletion was also observed in
various other preclinical models with OX40 agonists [224,
227]. Synergistic tumoricidal activity was further identified
in preclinical studies for combination of OX40 agonists
with, for example, cytokines such as IL-2 [228], with tumor
vaccination approaches [229], with adoptive T-cell transfer
[189], and by combination with a 4-1BB agonist antibody
[193].
9.2. Targeted OX40L-Based Cancer Immunotherapy. The pre-
viously described antibody-based OX40 agonist approaches
can potentially activate the OX40L/OX40 ligand/receptor
pair in a ubiquitous manner, which may translate into unan-
ticipated off-target effects particularly upon combinatorial
OX40-based therapeutic approaches. To achieve more selec-
tive tumor-specific activation of OX40 signaling on T-cells,
the OX40L can be incorporated into an antibody fragment-
targeted approach. Specifically, soluble homotrimeric OX40L
does not or only minimally induces OX40 signaling [230].
In contrast, hexameric OX40L proved to be fully capable
of activating OX40 [230], a finding corroborated by the
previously published co-stimulatory activity of the hexameric
OX40L:Fc fusion protein [131, 230]. Based on the previ-
ously described characteristics of the OX40/OX40L signaling
pathway, OX40L seems particularly amenable to targeted
delivery and activation. Indeed, antibody fragment-mediated
ISRN Oncology 17
delivery of sOX40L to the stromamarker FAP revealed potent
OX40-signaling activity on targeted cells (Figure 9) [230]. In
contrast, on FAP-negative cells this fusion protein remained
essentially inactive. Thus, this novel fusion protein appears
to fulfill the prerequisite of target-cell restricted activity and
may be a useful agent for the selective enhancement of
OX40-mediated T-cell co-stimulation in the tumor micro-
environment.
10. Conclusions
As discussed in this review, both proapoptotic and co-
stimulatory TNFL/TNFR ligand/receptor pairs hold consid-
erable promise for immunotherapy of cancer, with various
agonistic TNFR antibodies and recombinant soluble TNFLs
poised for or undergoing clinical evaluation. Indeed, the host
of ongoing preclinical studies and promising early clinical
results suggests that targeting of the TNFL/TNFR axis will
become part of clinical practice in the near future.
However, the ubiquitous activation of proapoptotic or
co-stimulatory TNFR signaling can have severe side-effects,
as evidenced by the early clinical experience with systemic
TNF infusion as well as the recent experience with systemic
agonistic 4-1BB antibody treatment. Thus, tumor-restricted
activation is being pursued in order to fully capitalize on
the therapeutic potential of this regulatory axis. In this
respect, antibody fragment-based fusion proteins of the
various TNFLs discussed here hold considerable promise.
Such targeted TNFLs selectively bind to a tumor target
antigen and, by virtue of the often reduced activity of soluble
homotrimeric ligand, are relatively inactive “en route.” How-
ever, once bound to the target antigen the ligand will acquire
tumoricidal or co-stimulatory activity resembling that of the
corresponding transmembrane ligands. For promiscuously
active ligands such as TNF the incorporation into advanced
prodrug strategies can further help to ensure strictly tumor-
localized unmasking of apoptotic activity.Thus, this targeting
approach may make significant headway towards a “magic
bullet” with maximum cancer-selective activity and minimal
side effects.
Further, as evident from early clinical trials with TRAIL-
receptor as well as CD40 agonists, single agent treatment
of patients will likely not yield sufficient clinical benefit.
In order to achieve meaningful clinical responses, design
of rational combinatorial strategies that ensure maximal
synergistic tumoricidal activity and minimal toxicity are
called for. Many such approaches have been initiated and
are currently being evaluated in preclinical studies as well
as early phase clinical trials. Of interest for proapoptotic
ligands/receptors are combinations that converge on known
antiapoptotic regulators of Death Receptor-mediated apop-
tosis. For co-stimulatory ligands/receptors, promising strate-
gies include those that shift the immune-inhibitory tumor
micro-environment towards an immune stimulatory tumor
micro-environment by, for example, targeted depletion of
regulatory T-cells and myeloid-derived suppressor cells.
Of note, an important issue that needs to be addressed for
any new type of immunotherapy to enter clinical practice is
the identification of appropriate patient stratification criteria.
In this respect, CD8+ T-cell infiltration and CD8+/Treg ratios
have prognostic value for patient survival and may also be
used to identify patients likely to respond to immunother-
apy [231]. The clinical activity of ipilimumab, for instance,
correlated well with high baseline expression of FoxP3 and
indoleamine 2,3-dioxygenase (IDO), an immunoregulatory
enzyme that suppresses T-cell responses, and high numbers
of tumor-infiltrating lymphocytes in a prospective phase
II clinical trial and these markers may thus be of use in
patient selection [232]. Thus, research in the upcoming years
should focus on not only identifying integratedTNFL/TNFR-
based combinatorial immunotherapeutics but also on the
identification of appropriate patient selection criteria.
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